Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug candidate AGSAVI aims to lower stubborn high blood pressure

NCT ID NCT05503953

Disease control Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This phase 3 study tests whether the drug AGSAVI can lower blood pressure in people with essential hypertension that is not well controlled by the drug AGLS. About 318 adults with high blood pressure will receive either AGSAVI or AGLS, and their sitting blood pressure will be measured over 10 weeks. The goal is to see if AGSAVI provides better blood pressure control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AGSAVI
What this could lead to
If successful, AGSAVI could offer a new treatment option for people with high blood pressure that is not well controlled by current medications.
What could go wrong
This is a phase 3 trial, but results may not confirm superiority or safety over existing treatments. Side effects are possible, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

318 people

The number who actually took part.

Started

Sep 2022

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hypertension patient who satisfied below condition at Visit 1. * patient who takes antihypertensive drug * 140mmHg \<= MSSBP \< 200mmHg * 130mmHg \<= MSSBP \< 200mmHg at or before visit 1(In high-risk patients) * patient who doesn't take antihypertensive drug * 160mmHg \<= MSSBP \< 200mmHg * Hypertension patient who satisfied below condition at Visit 2. * 140mmHg \<= MSSBP \< 200mmHg at Visit 2 * 130mmHg \<= MSSBP \< 200mmHg at or before Visit 1(In high-risk patients) Exclusion Criteria: * Patient who have received 4 or more antihypertensive drug * Patient with 20mmHg\>= of difference in MSSBP or 10mmHg\>= of difference in MSDBP BP measuring at Visit 1 * Patient with MSDBP \>= 120mmHg at Visit 1 and 2 * Patient with secondary hypertension(including past medical history)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential hypertension

Contacts and locations

Locations

  • AhnGook

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.